Publications by authors named "Ryan D Welch"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

25,953

Total Likes

609

Extended Reach

188,906

Social Features

12
E
Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH.
Ryan D Welch, Cyrielle Billon, McKenna Losby, Gonzalo Bedia-Diaz, Yuanying Fang

Metabolites· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intestinal α1-2-Fucosylation Contributes to Obesity and Steatohepatitis in Mice.
Rongrong Zhou, Cristina Llorente, Jinling Cao, Livia S Zaramela, Suling Zeng, Ryan D Welch

Cell Mol Gastroenterol Hepatol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rev-erbα heterozygosity produces a dose-dependent phenotypic advantage in mice.
Ryan D Welch, Cyrielle Billon, Amina Kameric, Thomas P Burris, Colin A Flaveny

PLoS One· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global chemical effects of the microbiome include new bile-acid conjugations.
Robert A Quinn, Alexey V Melnik, Alison Vrbanac, Ting Fu, Kathryn A Patras, Ryan D Welch

Nature· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological inhibition of REV-ERB stimulates differentiation, inhibits turnover and reduces fibrosis in dystrophic muscle.
Ryan D Welch, Cyrielle Billon, Aurore-Cecile Valfort, Thomas P Burris, Colin A Flaveny

Sci Rep· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rev-Erb co-regulates muscle regeneration via tethered interaction with the NF-Y cistrome.
Ryan D Welch, Chun Guo, Monideepa Sengupta, Katherine J Carpenter, Natalie A Stephens

Mol Metab· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REV-ERB and ROR: therapeutic targets for treating myopathies.
Ryan D Welch, Colin A Flaveny

Phys Biol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis.
Kristine Griffett, Ryan D Welch, Colin A Flaveny, Grant R Kolar, Brent A Neuschwander-Tetri

Mol Metab· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis